Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpha Tau MedicalDRTS -5.94%28 Earnings Yield (Joel Greenblatt) % is -8.02% as of Mar. 2026. GuruFocus rates DRTS with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,327 Biotechnology companies, Alpha Tau Medical ranks better than 64.96% on this metric.
Alpha Tau Medical's Enterprise Value for the quarter that ended in Mar. 2026 was $575.47 Mil.
Alpha Tau Medical's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-46.16 Mil. Alpha Tau Medical's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was -8.02%.
The historical rank and industry rank for Alpha Tau Medical's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
DRTS'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4.37 Med: 0 Max: 0
Current: -4.33
DRTS's Earnings Yield (Joel Greenblatt) % is ranked better than 64.96% of 1327
companies
in the Biotechnology industry
Industry Median: -10.16
vs DRTS: -4.33
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Alpha Tau Medical's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Alpha Tau Medical (NAS:DRTS) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Alpha Tau Medical Earnings Yield (Joel Greenblatt) % Related Terms
Alpha Tau Medical Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Alpha Tau Medical's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Tau Medical Earnings Yield (Joel Greenblatt) % Chart
For the Biotechnology subindustry, Alpha Tau Medical's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Tau Medical Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Alpha Tau Medical's Earnings Yield (Joel Greenblatt) % falls into.
Alpha Tau Medical Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Alpha Tau Medicals Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Alpha Tau Medical's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.16 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -8.02% mean?
Alpha Tau Medical (DRTS) has a Earnings Yield (Joel Greenblatt) % of -8.02% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Alpha Tau Medical and its competitors. According to the industry distribution chart, Alpha Tau Medical ranks #465 out of 1327 companies in the Biotechnology industry, placing it in the top 35%.
Is Alpha Tau Medical's Earnings Yield (Joel Greenblatt) % too high?
Alpha Tau Medical's current Earnings Yield (Joel Greenblatt) % is -8.02%. Based on the distribution chart, Alpha Tau Medical ranks #465 out of 1327 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alpha Tau Medical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's Earnings Yield (Joel Greenblatt) % compare to ORIC and OLMA?
According to the Biotechnology industry distribution chart, Alpha Tau Medical ranks #465 out of 1327 companies for Earnings Yield (Joel Greenblatt) %. This puts Alpha Tau Medical in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Alpha Tau Medical and its competitors. Alpha Tau Medical's current Earnings Yield (Joel Greenblatt) % is -8.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (DRTS) has a current Earnings Yield (Joel Greenblatt) % of -8.02%. The current Earnings Yield (Joel Greenblatt) % is -8.02%. Alpha Tau Medical's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Alpha Tau Medical (DRTS), the current Earnings Yield (Joel Greenblatt) % is -8.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
28GF Score
Get the complete analysis for DRTS
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRTS has been successfully added to your 
